Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; .
Novavax, Inc.February 26, 2021 GMT
Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in Japan
Takeda doses first participant in immunogenicity and safety study to support local regulatory application
GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in
GERAL :: Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico – Medialab estadao.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from estadao.com.br Daily Mail and Mail on Sunday newspapers.